139 related articles for article (PubMed ID: 34599114)
21. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India.
Joshi A; Zanwar S; Shetty N; Patil V; Noronha V; Bakshi G; Prakash G; Menon S; Prabhash K
Indian J Cancer; 2016; 53(2):313-316. PubMed ID: 28071636
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological features and survival of young Turkish patients with testicular germ cell tumors.
Ozgun A; Karagoz B; Tuncel T; Emirzeoglu L; Celik S; Bilgi O
Asian Pac J Cancer Prev; 2013; 14(11):6889-92. PubMed ID: 24377621
[TBL] [Abstract][Full Text] [Related]
24. Clinical Characteristics and Outcomes of Late Relapse in Stage I Testicular Seminoma.
Hosni A; Warde P; Jewett M; Bedard P; Hamilton R; Moore M; Nayan M; Huang R; Atenafu EG; O'Malley M; Sweet J; Chung P
Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):648-54. PubMed ID: 27339401
[TBL] [Abstract][Full Text] [Related]
25. Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.
Guney S; Guney N; Sonmez NC; Ergenekon E
Med Oncol; 2009; 26(2):136-42. PubMed ID: 18821067
[TBL] [Abstract][Full Text] [Related]
26. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
27. Part I: testicular cancer--management of early disease.
Jones RH; Vasey PA
Lancet Oncol; 2003 Dec; 4(12):730-7. PubMed ID: 14662429
[TBL] [Abstract][Full Text] [Related]
28. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
[TBL] [Abstract][Full Text] [Related]
30. Follow-up of clinical stage I testicular cancer patients: cost and risk benefit considerations.
Kakehi Y; Kamoto T; Kawakita M; Ogawa O
Int J Urol; 2002 Mar; 9(3):154-60; discussion 160-1. PubMed ID: 12010325
[TBL] [Abstract][Full Text] [Related]
31. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes.
Rice KR; Magers MJ; Beck SD; Cary KC; Einhorn LH; Ulbright TM; Foster RS
J Urol; 2014 Nov; 192(5):1403-9. PubMed ID: 24952240
[TBL] [Abstract][Full Text] [Related]
32. Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration.
Kildahl-Andersen A; Erke MG; Sagstuen H; Bremnes RM
Acta Oncol; 2005; 44(6):537-44. PubMed ID: 16165912
[TBL] [Abstract][Full Text] [Related]
33. Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumours.
Colls BM; Harvey VJ; Skelton L; Thompson PI; Dady PJ; Forgeson GV; Perez DJ
Br J Urol; 1992 Oct; 70(4):423-8. PubMed ID: 1333336
[TBL] [Abstract][Full Text] [Related]
34. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis.
Ramani VA; Grey BR; Addla SK; Dunham MP; Sangar VK; Clarke NW
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):247-52. PubMed ID: 18093814
[TBL] [Abstract][Full Text] [Related]
35. Rare Tumours of the Testis: Twelve Years of Experience.
Oruc Z; Ebinç S; Kaplan MA
Prague Med Rep; 2020; 121(3):181-193. PubMed ID: 33030147
[TBL] [Abstract][Full Text] [Related]
36. Leukocyte and platelet counts as prognostic values of testicular germ cell tumours.
Herraiz-Raya L; Moreillo-Vicente L; Martínez-Ruiz J; Agustí-Martínez A; Fernández-Anguita PJ; Esper-Rueda JA; Salce-Marte L; Armas-Álvarez A; Díaz de Mera-Sánchez Migallón I; Martínez-Alfaro C; Giménez-Bachs JM; Donate-Moreno MJ; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2019; 43(6):284-292. PubMed ID: 31085041
[TBL] [Abstract][Full Text] [Related]
37. The management and outcome of patients with germ-cell tumours treated in the Edinburgh Cancer Centre between 1988 and 2002.
Howard GC; Conkey DS; Peoples S; McLaren DB; Hargreave TB; Tulloch DN; Walker W; Kerr GR
Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):435-40. PubMed ID: 16149287
[TBL] [Abstract][Full Text] [Related]
38. Compliance of males with stage 1 testicular germ cell tumours on an active surveillance protocol.
Honeyball F; Murali-Ganesh R; Hruby G; Grimison P
Intern Med J; 2015 Oct; 45(10):1081-4. PubMed ID: 26429219
[TBL] [Abstract][Full Text] [Related]
39. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort.
Daugaard G; Gundgaard MG; Mortensen MS; Agerbæk M; Holm NV; Rørth M; von der Maase H; Christensen IJ; Lauritsen J
J Clin Oncol; 2014 Dec; 32(34):3817-23. PubMed ID: 25267754
[TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy and Retroperitoneal Lymph Node Dissection for the Management of Early Stage Testicular Germ Cell Tumors: A Systematic Review.
Pierorazio PM; Cheaib JG; Patel HD; Gupta M; Sharma R; Zhang A; Tema G; Bass EB
J Urol; 2021 Feb; 205(2):370-382. PubMed ID: 32915080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
